The prognostic significance of growth factors and growth factor receptors in gastric adenocarcinoma

APMIS

Volumn 121, Issue 2, 2013, Pages 95-104

  Kim, Jung Yeon ^a   Jeon, Tae Joo ^a   Bae, Byung Noe ^a   Kwon, Ji Eun ^a   Kim, Hyun Jung ^a   Park, Kyeongmee ^a   Shin, Eunah ^b  

^a Inje University College of Medicine   (South Korea)

^b CFC Pathology Laboratory   (South Korea)

Author keywords

Adenocarcinoma; Stomach; TGF; VEGF D; VEGFR 2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; FEMALE; GASTRITIS; GASTROINTESTINAL DYSPLASIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METAPLASIA; PERINEUM; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; TISSUE MICROARRAY; TUMOR LOCALIZATION;

CLONING, MOLECULAR; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84872659916     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2012.02942.x     Document Type: Article

References (42)

1. Lauwers G. Epithelial neoplasms of the stomach. In: Odze R, Goldblum J, editors. Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. 2nd ed. Philadelphia: Saunders Elsevier; 2009:564-5.
2. Iqbal S, Lenz HJ. Angiogenesis inhibitors in the treatment of colorectal cancer. Semin Oncol 2004;31:10-6.
3. Pisick E, Jagadeesh S, Salgia R. Receptor tyrosine kinases and inhibitors in lung cancer. ScientificWorldJournal 2004;4:589-604.
4. McCarty MF, Wey J, Stoeltzing O, Liu W, Fan F, Bucana C, et al. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther 2004;3:1041-8.
5. Trojan L, Thomas D, Knoll T, Grobholz R, Alken P, Michel MS. Expression of pro-angiogenic growth factors VEGF, EGF and bFGF and their topographical relation to neovascularisation in prostate cancer. Urol Res 2004;32:97-103.
6. Yokoi K, Sasaki T, Bucana CD, Fan D, Baker CH, Kitadai Y, et al. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res 2005;65:10371-80.
7. Eriksson U, Alitalo K. Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr Top Microbiol Immunol 1999;237:41-57.
8. Sancho P, Bertran E, Caja L, Carmona-Cuenca I, Murillo MM, Fabregat I. The inhibition of the epidermal growth factor (EGF) pathway enhances TGF-beta-induced apoptosis in rat hepatoma cells through inducing oxidative stress coincident with a change in the expression pattern of the NADPH oxidases (NOX) isoforms. Biochim Biophys Acta 2009;1793:253-63.
9. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001;8:3-9.
10. Herbst RS, Sandler AB. Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2004;6(Suppl 1):S7-19.
11. Maae E, Olsen DA, Steffensen KD, Jakobsen EH, Brandslund I, Sorensen FB, et al. Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer. Breast Cancer Res Treat 2012;133:257-65.
12. Hess C, Vuong V, Hegyi I, Riesterer O, Wood J, Fabbro D, et al. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer 2001;85:2010-6.
13. Takahashi O, Komaki R, Smith PD, Jurgensmeier JM, Ryan A, Bekele BN, et al. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. Clin Cancer Res 2012;18:1641-54.
14. Gershtein ES, Kushlinsky DN, Levkina NV, Tereshkina IV, Nosov VB, Laktionov KP, et al. Relationship between the expression of VEGF signal components and matrix metalloproteinases in ovarian tumors. Bull Exp Biol Med 2011;151:449-53.
15. Awazu Y, Mizutani A, Nagase Y, Iwata H, Oguro Y, Miki H, et al. A novel pyrrolo[3, 2-d]pyrimidine derivative, as a vascular endothelial growth factor receptor and platelet-derived growth factor receptor tyrosine kinase inhibitor, shows potent antitumor activity by suppression of tumor angiogenesis. Cancer Sci 2012;103:934-44.
16. Pajares MJ, Agorreta J, Larrayoz M, Vesin A, Ezponda T, Zudaire I, et al. Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J Clin Oncol 2012;30:1129-36.
17. Kim JY, Lim SJ, Park K, Lee CM, Kim J. Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays. Gynecol Oncol 2005;97:337-41.
18. Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805.
19. Hiro J, Inoue Y, Toiyama Y, Miki C, Kusunoki M. Mechanism of resistance to chemoradiation in p53 mutant human colon cancer. Int J Oncol 2008;32:1305-10.
20. Rossi E, Villanacci V, Danesino C, Donato F, Nascimbeni R, Bassotti G. Epidermal growth factor receptor overexpression/amplification in adenocarcinomas arising in the gastrointestinal tract. Rev Esp Enferm Dig 2012;103:632-9.
21. Song K, Krebs TL, Danielpour D. Novel permissive role of epidermal growth factor in transforming growth factor beta (TGF-beta) signaling and growth suppression. Mediation by stabilization of TGF-beta receptor type II. J Biol Chem 2006;281:7765-74.
22. Danielpour D, Song K. Cross-talk between IGF-I and TGF-beta signaling pathways. Cytokine Growth Factor Rev 2006;17:59-74.
23. Song K, Cornelius SC, Danielpour D. Development and characterization of DP-153, a nontumorigenic prostatic cell line that undergoes malignant transformation by expression of dominant-negative transforming growth factor beta receptor type II. Cancer Res 2003;63:4358-67.
24. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 2003;100:8621-3.
25. Kim IY, Ahn HJ, Lang S, Oefelein MG, Oyasu R, Kozlowski JM, et al. Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients. Clin Cancer Res 1998;4:1625-30.
26. Kim SJ, Im YH, Markowitz SD, Bang YJ. Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis. Cytokine Growth Factor Rev 2000;11:159-68.
27. McCaffrey TA, Du B, Fu C, Bray PJ, Sanborn TA, Deutsch E, et al. The expression of TGF-beta receptors in human atherosclerosis: evidence for acquired resistance to apoptosis due to receptor imbalance. J Mol Cell Cardiol 1999;31:1627-42.
28. Kim JY, Park DY, Kim GH, Choi KU, Lee CH, Huh GY, et al. Smad4 expression in gastric adenoma and adenocarcinoma: frequent loss of expression in diffuse type of gastric adenocarcinoma. Histol Histopathol 2005;20:543-9.
29. Kiyono K, Suzuki HI, Morishita Y, Komuro A, Iwata C, Yashiro M, et al. c-Ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric carcinoma. Cancer Sci 2009;100:1809-16.
30. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M, et al. The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer 1999;86:1455-62.
31. Wang Y, Crisostomo PR, Wang M, Markel TA, Novotny NM, Meldrum DR. TGF-alpha increases human mesenchymal stem cell-secreted VEGF by MEK- and PI3-K- but not JNK- or ERK-dependent mechanisms. Am J Physiol Regul Integr Comp Physiol 2008;295:R1115-23.
32. Wang Y, Wang M, Abarbanell AM, Weil BR, Herrmann JL, Tan J, et al. MEK mediates the novel cross talk between TNFR2 and TGF-EGFR in enhancing vascular endothelial growth factor (VEGF) secretion from human mesenchymal stem cells. Surgery 2009;146:198-205.
33. Ferrari G, Pintucci G, Seghezzi G, Hyman K, Galloway AC, Mignatti P. VEGF, a prosurvival factor, acts in concert with TGF-beta1 to induce endothelial cell apoptosis. Proc Natl Acad Sci USA 2006;103:17260-5.
34. Ferrari G, Cook BD, Terushkin V, Pintucci G, Mignatti P. Transforming growth factor-beta 1 (TGF-beta1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. J Cell Physiol 2009;219:449-58.
35. Pardali K, Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 2007;1775:21-62.
36. Kojima H, Shijubo N, Yamada G, Ichimiya S, Abe S, Satoh M, et al. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. Cancer 2005;104:1668-77.
37. Juttner S, Wissmann C, Jons T, Vieth M, Hertel J, Gretschel S, et al. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 2006;24:228-40.
38. Carrillo-de Santa Pau E, Carrillo Arias F, Caso Pelaez E, Muguruza Trueba I, Sánchez Hernández I, Muñoz Molina GM, et al. Vascular endothelial growth factor (VEGF) serum levels are associated with survival in early stages of lung cancer patients. Cancer Invest 2009;28:393-8.
39. Witte D, Thomas A, Ali N, Carlson N, Younes M. Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma. Anticancer Res 2002;22:1463-6.
40. Schimanski CC, Schlaegel F, Jordan M, Moehler M, Sgourakis G, Drescher DG, et al. VEGF-D correlates with metastatic disease in gastric cancer patients undergoing surgery. World J Surg 2011;35:1010-6.
41. Kim JY, Bae BN, Kwon JE, Kim HJ, Park K. Prognostic significance of epidermal growth factor receptor and vascular endothelial growth factor receptor in colorectal adenocarcinoma. APMIS 2011;119:449-59.
42. Benedito R, Rocha SF, Woeste M, Zamykal M, Radtke F, Casanovas O, et al. Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling. Nature 2012;484:110-4.